0      0


AM22-61-O - AM22-61-O: (On-Demand) New Frontiers for Unmanipulated Cord Blood as Well as Its Derivatives (Enduring)


‐ Nov 7, 2022 6:00pm

Expiration Date: Dec 31, 2024


Credits: None available.

The advent of haploidentical transplants has led to a decline in cord blood (CB) transplants, especially considering the cost of double-cord transplants. Cord blood expansion techniques, while promising, are likely to be expensive. In this session, a speaker will describe the advantages of combined haplo-unmanipulated CB transplants, including the recent cure of both HIV and myeloid malignancy with this method, and adoptive immunotherapy with unmanipulated CB following chemotherapy for refractory myeloid malignancy. Another speaker will describe the utility of pluripotent stem cells derived from CB in comparison to other starting material sources. They will also review the clinical success with CB-derived immune effector cells such as NK cells and T-regulatory cells.

All relevant financial relationships have been mitigated.


Learning Objectives:

  • Describe the limitations and advantages of combined haplo-unmanipulated cord blood transplants.
  • Discuss adoptive immunotherapy with unmanipulated CB units for refractory myeloid malignancy.
  • Review the utility of CB-derived pluripotent stem cells as well as CB-derived immune effector cells.

Disclosures

  • Patricia Shi, MD:

    Global Blood Therapeutics: Grant/Research Support

  • Larry Luchsinger, PhD:

    Nothing to Disclose

  • Koen van Besien, MD, PhD:

    Hemogenyx, Intellia, Glycostem, Gamida Biosciences, CTI: Consultant

    Pfizer: Speaker's Bureau

    ADC Therapeutics, Autolus, Intellia: member DSMB

    Miltenyi Biotec, Precision Biosciencs, Orca Biotherapeutics, BMS, Caibr: Grant/Research Support

By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.

Credits Available


AM22-61-O: (On-Demand) New Frontiers for Unmanipulated Cord Blood as Well as Its Derivatives (Enduring) Evaluation